Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation
Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is an important cause of morbidity and mortality in heart transplant (HTx) recipients. However, previous studies of PTLD after HTx are limited to single-center analyses or extrapolated from all solid organ transplantations.
OBJECTIVES: The authors analyzed the temporal trends, risk factors, and clinical outcome of de novo PTLD specifically after HTx.
METHODS: Using multi-institutional, multinational data from the International Society for Heart and Lung Transplantation Thoracic Organ Transplant Registry, the authors evaluated the real-world data of PTLD after HTx, transplanted between January 2000 and June 2015. Multivariable analysis was done to identify risk factors for PTLD development after HTx.
RESULTS: Among 28,136 HTx recipients, 1,069 (3.8%) developed PTLD within 10 years of transplantation. PTLD showed a bimodal age pattern with peak incidence in patients of pediatric age and late adulthood at transplantation. The early transplant era (2000-2007 vs 2008-2015), male recipient, and EBV donor-positive-recipient-negative match were independent risk factors of PTLD development within 3 years of transplantation, whereas maintenance therapy with cyclosporine vs tacrolimus at initial discharge was associated with a lower incidence. PTLD development within 3 years of transplantation was significantly associated with mortality (HR: 2.42 [95% CI: 2.01-2.91]; P < 0.001). Survival after PTLD diagnosis was higher in the recent transplant era.
CONCLUSIONS: PTLD is relatively rare, but potentially fatal, post-transplant malignancy. PTLD incidence and mortality after HTx have decreased in the recent era. Strategies to minimize the risk of PTLD, and ensure early diagnosis and effective treatment are likely to improve outcomes in HTx.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
JACC. Heart failure - 12(2024), 2 vom: 27. Feb., Seite 395-405 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, In-Cheol [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cyclosporine |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 23.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jchf.2023.10.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368152367 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368152367 | ||
| 003 | DE-627 | ||
| 005 | 20240229150027.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240208s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jchf.2023.10.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM368152367 | ||
| 035 | |a (NLM)38326002 | ||
| 035 | |a (PII)S2213-1779(23)00752-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, In-Cheol |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is an important cause of morbidity and mortality in heart transplant (HTx) recipients. However, previous studies of PTLD after HTx are limited to single-center analyses or extrapolated from all solid organ transplantations | ||
| 520 | |a OBJECTIVES: The authors analyzed the temporal trends, risk factors, and clinical outcome of de novo PTLD specifically after HTx | ||
| 520 | |a METHODS: Using multi-institutional, multinational data from the International Society for Heart and Lung Transplantation Thoracic Organ Transplant Registry, the authors evaluated the real-world data of PTLD after HTx, transplanted between January 2000 and June 2015. Multivariable analysis was done to identify risk factors for PTLD development after HTx | ||
| 520 | |a RESULTS: Among 28,136 HTx recipients, 1,069 (3.8%) developed PTLD within 10 years of transplantation. PTLD showed a bimodal age pattern with peak incidence in patients of pediatric age and late adulthood at transplantation. The early transplant era (2000-2007 vs 2008-2015), male recipient, and EBV donor-positive-recipient-negative match were independent risk factors of PTLD development within 3 years of transplantation, whereas maintenance therapy with cyclosporine vs tacrolimus at initial discharge was associated with a lower incidence. PTLD development within 3 years of transplantation was significantly associated with mortality (HR: 2.42 [95% CI: 2.01-2.91]; P < 0.001). Survival after PTLD diagnosis was higher in the recent transplant era | ||
| 520 | |a CONCLUSIONS: PTLD is relatively rare, but potentially fatal, post-transplant malignancy. PTLD incidence and mortality after HTx have decreased in the recent era. Strategies to minimize the risk of PTLD, and ensure early diagnosis and effective treatment are likely to improve outcomes in HTx | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ebstein-Barr virus | |
| 650 | 4 | |a cyclosporine | |
| 650 | 4 | |a heart transplant | |
| 650 | 4 | |a lymphoproliferative disorder | |
| 650 | 4 | |a post-transplant lymphoproliferative disorder | |
| 700 | 1 | |a Kim, Sang Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Youn, Jong-Chan |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Darae |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Seonhwa |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyungseop |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jin-Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Mi-Hyang |e verfasserin |4 aut | |
| 700 | 1 | |a Rossano, Joseph W |e verfasserin |4 aut | |
| 700 | 1 | |a Cherikh, Wida S |e verfasserin |4 aut | |
| 700 | 1 | |a Kobashigawa, Jon A |e verfasserin |4 aut | |
| 700 | 1 | |a Stehlik, Josef |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JACC. Heart failure |d 2013 |g 12(2024), 2 vom: 27. Feb., Seite 395-405 |w (DE-627)NLM22747550X |x 2213-1787 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:2 |g day:27 |g month:02 |g pages:395-405 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jchf.2023.10.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 2 |b 27 |c 02 |h 395-405 | ||